Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT02413489
Registration number
NCT02413489
Ethics application status
Date submitted
7/04/2015
Date registered
10/04/2015
Date last updated
26/06/2018
Titles & IDs
Public title
An Efficacy and Safety Proof of Concept Study of Daratumumab in Relapsed/Refractory Mantle Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma
Query!
Scientific title
An Open Label, Phase 2 Study to Evaluate Efficacy and Safety of Daratumumab in Relapsed or Refractory Mantle Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma
Query!
Secondary ID [1]
0
0
54767414LYM2001
Query!
Secondary ID [2]
0
0
CR106660
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Lymphoma, Mantle-Cell
0
0
Query!
Lymphoma, Large B-Cell, Diffuse
0
0
Query!
Lymphoma, Follicular
0
0
Query!
Condition category
Condition code
Cancer
0
0
0
0
Query!
Lymphoma (non Hodgkin's lymphoma) - High grade lymphoma
Query!
Cancer
0
0
0
0
Query!
Lymphoma (non Hodgkin's lymphoma) - Low grade lymphoma
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Daratumumab
Experimental: Daratumumab - Participants will receive daratumumab (16 milligram per kilogram [mg/kg]) as intravenous infusion once every week for 8 weeks; then once every other week for 16 weeks; thereafter once every 4 weeks until documented progression, unacceptable toxicity, or study end.
Treatment: Drugs: Daratumumab
Daratumumab 16 mg/kg will be administered as intravenous infusion to participants once every week for 8 weeks; then once every other week for 16 weeks; thereafter once every 4 weeks until documented progression, unacceptable toxicity, or study end.
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Overall Response Rate (ORR)
Query!
Assessment method [1]
0
0
ORR was defined as the percentage of participants who achieved complete response (CR) or partial response (PR). As per Revised Response Criteria for Malignant Lymphoma, Lymph node measurements were taken from Computed Tomography (CT), CT portion of the Positron Emission Tomography/Computed Tomography (PET/CT), or Magnetic resonance imaging (MRI) scans where applicable. CR is defined as complete disappearance of all evidence of disease; PR as a greater than (>) 50 percent (%) decrease in the sum of the products of the maximal perpendicular diameters of measured lesions (SPD) and no new sites.
Query!
Timepoint [1]
0
0
After the first dose until disease progression, withdrawal of consent from study participation, or the end of study (approximately 1.9 years)
Query!
Secondary outcome [1]
0
0
Duration of Response
Query!
Assessment method [1]
0
0
Duration of response was the duration from the date of the initial documentation of a response to the date of first documented evidence of progressive disease (PD). PD is defined as any new lesion >1.5 centimeter (cm) in any axis or greater than or equal to (>=) 50% increase in previously involved sites.
Query!
Timepoint [1]
0
0
Approximately 1.9 years
Query!
Secondary outcome [2]
0
0
Progression Free Survival (PFS)
Query!
Assessment method [2]
0
0
PFS was defined as the duration from the date of the first daratumumab dose to the date of progression or death, whichever comes first.
Query!
Timepoint [2]
0
0
Approximately 1.9 years
Query!
Secondary outcome [3]
0
0
Overall Survival (OS)
Query!
Assessment method [3]
0
0
Overall survival was defined as the duration from the date of the first daratumumab dose to the date of death.
Query!
Timepoint [3]
0
0
Approximately 1.9 years
Query!
Secondary outcome [4]
0
0
Time to Response
Query!
Assessment method [4]
0
0
Time to response was defined as the duration from the date of the first dose of daratumumab to the earliest date that a response (CR/PR) is first documented.
Query!
Timepoint [4]
0
0
Approximately 1.9 years
Query!
Eligibility
Key inclusion criteria
- Has diagnosis and prior treatment for each non-hodgkin's lymphoma (NHL) subtype as
defined below: Mantle cell lymphoma (MCL): pathologically verified diagnosis of MCL
based on local pathology report, relapsed or refractory disease after at least 2 prior
lines of therapy, including at least 1 cycle of Bruton's tyrosine kinase (BTK)
inhibitor therapy and documented progressive disease (PD) during or after BTK
inhibitor treatment or participants who could not tolerate BTK inhibitor [ie,
discontinued BTK inhibitor due to adverse events (AEs)], b) Diffuse large B cell
lymphoma (DLBCL): pathologically confirmed diagnosis of non-transformed DLBCL, and
relapsed or refractory disease; for those participants who have not received HDT/ASCT
are not eligible for HDT/ASCT due to comorbidities, c) Follicular lymphoma (FL):
pathologically confirmed diagnosis of FL of Grade 1, 2, or 3a according to World
Health Organization (WHO) criteria without pathological evidence of transformation,
and relapsed disease after at least two prior systemic therapies including one
anti-CD20 containing combination regimen
- At least 1 measurable site of disease
- Participants must have available archival or fresh tumor tissue or both to submit to a
central laboratory for CD38 assay. Expression of CD38 is measured by
immunohistochemistry on fresh or archived tumor sample by central assessment using a
CD38 investigational IHC assay under development: a) Stage 1: participants whose
tumors are more than or equal to (>=) 50 percent (%) positive for CD38, b) Stage 2:
participant has less than (<) 50% CD38+ or greater than (>) 50% CD38+ depending on the
distribution of CD 38 expression of enrolled participants during Stage 2. The sponsor
will advise on which eligibility criterion is permitted during the enrollment period
- Participant must have an ECOG performance status score of 0 or 1
- Women of childbearing potential must be practicing a highly effective method of birth
control consistent with local regulations regarding the use of birth control methods
for participants participating in clinical studies: example, established use of oral,
injected or implanted hormonal methods of contraception; placement of an intrauterine
device (IUD) or intrauterine system (IUS); barrier methods: condom with spermicidal
foam/gel/film/cream/suppository or occlusive cap (diaphragm or cervical/vault caps)
with spermicidal foam/gel/film/cream/suppository; male partner sterilization (the
vasectomized partner should be the sole partner for that participant); true abstinence
(when this is in line with the preferred and usual lifestyle of the participant)
during and after the study (3 months after the last dose of any component of the
treatment regimen)
- A woman of childbearing potential must have a negative serum or urine pregnancy test
within 14 days before commencing treatment. Females of reproductive potential must
commit either to abstain continuously from heterosexual sexual intercourse or to use 2
methods of reliable birth control simultaneously
- A man who is sexually active with a woman of childbearing potential and has not had a
vasectomy must agree to use a barrier method of birth control example, either condom
with spermicidal foam/gel/film/cream/suppository or partner with occlusive cap
(diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository,
and all men must also not donate sperm during the study and for 3 months after
receiving the last dose of any component of the treatment regimen. The exception to
this restriction is that if the participant's female partner is surgically sterile, a
second method of birth control is not required
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- Known central nervous system lymphoma
- Prior anti-tumor therapy including (all times measured prior to start of study drug):
nitrosoureas within 6 weeks, chemotherapy within 3 weeks, therapeutic antibodies
within 4 weeks, radio- or toxin-immunoconjugates within 10 weeks, radiation therapy
within 2 weeks, investigational agents within 3 weeks, unless antibody this should be
within 4 weeks
- Daratumumab or other anti-CD38 therapies
- Participant has a history of malignancy (other than NHL) within 3 years before the
screening period (exceptions are squamous and basal cell carcinomas of the skin and
carcinoma in situ of the cervix, non-muscle invasive bladder cancer (papillary
neoplasms of low malignant potential and primary non-invasive tumors), or malignancy
that in the opinion of the investigator, with concurrence with the sponsor's medical
monitor, is considered cured with minimal risk of recurrence within 2 years)
- Participant has known chronic obstructive pulmonary disease (COPD) with a Forced
Expiratory Volume in 1 second (FEV1) less than (<) 50% predicted normal. Note that
FEV1 testing is required for participants suspected of having COPD and participants
must be excluded if FEV1 <50% b) Participant has known moderate or severe persistent
asthma within 2 years (see Attachment 4: NHLBI table of asthma severity), or currently
has uncontrolled asthma of any classification. (Note that participants who currently
have controlled intermittent asthma or controlled mild persistent asthma are allowed
in the study)
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
N/A
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Single group
Query!
Other design features
Query!
Phase
Phase 2
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Terminated
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
2/09/2015
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
1/06/2017
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
36
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Recruitment hospital [1]
0
0
- Adelaide
Query!
Recruitment hospital [2]
0
0
- Box Hill
Query!
Recruitment hospital [3]
0
0
- Melbourne
Query!
Recruitment postcode(s) [1]
0
0
- Adelaide
Query!
Recruitment postcode(s) [2]
0
0
- Box Hill
Query!
Recruitment postcode(s) [3]
0
0
- Melbourne
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
California
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Florida
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Georgia
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Illinois
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Kentucky
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Maryland
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Minnesota
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Nebraska
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
New Jersey
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Pennsylvania
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Texas
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Washington
Query!
Country [13]
0
0
Belgium
Query!
State/province [13]
0
0
Brugge
Query!
Country [14]
0
0
Belgium
Query!
State/province [14]
0
0
Gent
Query!
Country [15]
0
0
France
Query!
State/province [15]
0
0
Lille
Query!
Country [16]
0
0
France
Query!
State/province [16]
0
0
Limoges Cedex
Query!
Country [17]
0
0
France
Query!
State/province [17]
0
0
Nantes Cedex 01
Query!
Country [18]
0
0
France
Query!
State/province [18]
0
0
Paris Cedex 10
Query!
Country [19]
0
0
France
Query!
State/province [19]
0
0
Pessac
Query!
Country [20]
0
0
France
Query!
State/province [20]
0
0
Pierre Benite
Query!
Country [21]
0
0
France
Query!
State/province [21]
0
0
Rouen Cedex
Query!
Country [22]
0
0
Korea, Republic of
Query!
State/province [22]
0
0
Goyang-Si
Query!
Country [23]
0
0
Korea, Republic of
Query!
State/province [23]
0
0
Seoul
Query!
Country [24]
0
0
Netherlands
Query!
State/province [24]
0
0
Amsterdam
Query!
Country [25]
0
0
Netherlands
Query!
State/province [25]
0
0
Rotterdam
Query!
Country [26]
0
0
Netherlands
Query!
State/province [26]
0
0
Utrecht
Query!
Country [27]
0
0
Turkey
Query!
State/province [27]
0
0
Ankara
Query!
Country [28]
0
0
Turkey
Query!
State/province [28]
0
0
Atakum
Query!
Country [29]
0
0
Turkey
Query!
State/province [29]
0
0
Istanbul
Query!
Country [30]
0
0
Turkey
Query!
State/province [30]
0
0
Kocaeli
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Janssen Research & Development, LLC
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The purpose of this study is to assess overall response rate [ORR, including complete
response (CR) and partial response (PR)], of daratumumab in participants with non-Hodgkin's
lymphoma [a cancer of the lymph nodes (or tissues)-NHL] and to evaluate association between
ORR and CD38 expression level in order to determine a threshold for CD38 expression level in
each NHL subtype, above which daratumumab activity is enhanced in participants with relapsed
or refractory mantle cell lymphoma, diffuse large B-cell lymphoma, and follicular lymphoma.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT02413489
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Janssen Research & Development, LLC Clinical Trial
Query!
Address
0
0
Janssen Research & Development, LLC
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT02413489
Download to PDF